Tech Company Financing Transactions
Walden Biosciences Funding Round
Private investors participated in a $51 million Series A capital raise for Walden Biosciences. The round was announced on 10/7/2020.
Transaction Overview
Company Name
Announced On
10/7/2020
Transaction Type
Venture Equity
Amount
$51,000,000
Round
Series A
Investors
Proceeds Purpose
Walden will use the funding--which came from Arch and UCB Ventures--to get both programs into the clinic and add a few new members to the team.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. 7102
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We utilize our mechanistic understanding of kidney function in health and disease to provide patients with real treatment options, which target the kidney at the site of drug action.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Blaine McKee
Chief Scientific Officer
Alex Duncan
Browse more venture capital transactions:
Prev: 10/7/2020: Evrything venture capital transaction
Next: 10/7/2020: Tipalti venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs